<DOC>
	<DOCNO>NCT02443103</DOCNO>
	<brief_summary>This study explore biologic activity guanabenz reduce bone turn solid tumor patient bone metastasis . If successful , repurposing already , generic drug could benefit patient faster manufacture novel expensive compound .</brief_summary>
	<brief_title>Study Evaluating Biologic Activity Guanabenz Bone Metastasis</brief_title>
	<detailed_description>OBJECTIVES Primary Objective : Evaluate biologic effect guanabenz marker bone formation bone resorption patient solid tumor bone metastasis . Secondary Objectives : ( 1 ) Compare guanabenz exposure patient base limited PK sampling activity observe previous pre-clinical study ; ( 2 ) Assess safety/tolerability guanabenz ; ( 3 ) Evaluate biologic effect guanabenz bone metabolism marker . Tertiary Objective : Compare change bone turn marker ( formation , resorption metabolism ) achieve guanabenz change bone turn marker standard care ( bisphosphonate/denosumab ) . STUDY DESIGN This exploratory pilot study evaluate biologic effect guanabenz bone formation bone resorption marker patient solid tumor bone metastasis . PROCEDURES All register patient receive oral guanabenz first two month prior start standard care skeletal protective therapy . All patient study receive standard care systemic treatment underlie solid malignancy deem necessary treating physician . Guanabenz administer concurrently primary cancer systemic treatment . However patient withhold standard care bone direct therapy 8 week . The study exclude patient immediate need treatment . Patients experience skeletal related event study withdrawn . Delaying standard care skeletal therapy 2 month consider major deviation long therapy delay necessary purpose deem treat physician . Patients know hypertension antihypertensive medication study enrollment eligible participate . Antihypertensive medication change result study enrollment unless deem necessary treating physician ; dose guanabenz adjust . TREATMENT Patients begin take 8 mg mouth ( PO ) bed time ( HS ) start day 1 one week . The dose increase 8 mg PO twice day ( BID ) ( 8 mg daily morning ( QAM ) 8 mg daily evening ( QPM ) total 16 mg ) day 8 ( +/-3 day ) , increase 8 mg PO QAM 16 mg PO QPM ( total 24 mg ) day 15 ( +/- 3 day ) , increase 16 mg PO BID ( 16 mg QAM 16 mg QPM total 32 mg ) day 22 . Patients continue maximum tolerate dose ( MTD ) day 56 ( +/- 3 day ) . The dose wean patient receive 8 mg daily complete week 8 standard care skeletal protective therapy begin . Guanabenz wean week 11 , patient continue standard care skeletal protective therapy deem necessary treating physician . To ensure patient safety dose escalation throughout study , patient provide taught use home blood pressure ( BP ) monitoring . We instruct patient check BP 2 hour guanabenz dose escalation least three time weekly . Patients maintain diary BP result dose escalation phase . Patients report hypotensive measurement research nurse define least two reading less &lt; 100/60 mm Hg sit position take 30 min apart . At visit , blood pressure adverse event assess . Dose escalation continue guanabenz BP &gt; = 110/70 mm Hg and/or unacceptable toxicity . Guanabenz take instructed empty stomach . If patient miss dose guanabenz , he/she take miss dose later 3 hour instructed time continue schedule . On day 57 ( +/- 3 day ) , study patient start guanabenz wean . All patient receive ongoing standard care skeletal protective therapy ( denosumab/zometa ) determine treat physician begin wean phase .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Bone Neoplasms</mesh_term>
	<mesh_term>Osteosarcoma</mesh_term>
	<mesh_term>Guanabenz</mesh_term>
	<criteria>1 . â‰¥ 18 year old time inform consent 2 . Ability provide write informed consent HIPAA authorization 3 . Solid organ malignancy document bone metastasis image 4 . Adequate liver function ( serum total bilirubin &lt; = 3 AST/ALT &lt; = 3 time upper normal limit ) 5 . Adequate renal function ( serum creatinine &lt; = 2mg/dL ) 6 . Ability swallow oral tablet 7 . Females childbearing potential must negative pregnancy test &lt; = 28 day prior registration . All female childbearing potential sexually active , must agree use highly reliable method contraception prevent pregnancy . These include abstinence , partner previous vasectomy , placement intrauterine device ( IUD ) , condom spermicidal foam/gel/film/cream/suppository , diaphragm cervical vault cap , hormonal birth control ( pill injection ) . NOTE : Females consider childbearing potential unless surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal ( &gt; 12 month since last menses ) . 8 . Patients permit participate clinical trial participate trial . 9 . Patients receive standard care systemic treatment underlie solid malignancy deem necessary treating physician . 1 . No prior history bisphosphonate ordenosumab use past 12 month 2 . No history SRE within past 3 month 1 . Excruciating bone pain require RT 2 . Cord compression 3 . Hypercalcemia [ serum calcium &gt; 10.5 ] 4 . Pathologic fracture 3 . No history Paget 's disease 4 . No history epilepsy/seizures 5 . No history hypotension ( define rest systolic blood pressure &lt; 110 mm Hg diastolic blood pressure &lt; 70 mm Hg ) orthostasis ( define drop systolic blood pressure &gt; 20 mm Hg increase HR &gt; 20 supine stand position ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>pilot study</keyword>
	<keyword>guanabenz acetate</keyword>
</DOC>